The effectiveness of the vaccine candidates from Moderna and Pfizer is promising, but startups should remain cautious about how this will impact businesses and the economy.

Access to capital and FDA's development strategies for rare diseases have enabled small biotech companies to bring products to market without being acquired.

The future holds the potential to eradicate diseases, with nonprofits working to identify all human druggable targets to aid the drug industry.

In the current environment, the focus should be on developing products that can demonstrate clear impact on patients, whether through safety or efficacy.

Recent approvals of gene therapies and cell-based therapies have opened new avenues for biotech companies to create marketable products.

Investing in defense tech is booming, but the market is not as limitless as it seems; there are mature and emergent competitors, and the available budget is often more constrained than perceived.

When evaluating biotech companies, the demand for their product is often clear, but the challenge lies in their ability to deliver on that promise.

Vaccines can cause an inflammatory response, and in rare cases, this response may impact neurodevelopment in susceptible individuals, particularly those with pre-existing conditions.

There's a lot of innovation in the biomedical field that isn't covered by patents, which can hinder the development of beneficial treatments. For example, mannose, a sugar that may have potential as an onco-treatment, lacks funding because it cannot be patented.